Free Trial

Miragen Therapeutics (MGEN) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
50-Day Range
52-Week Range
625,309 shs
Average Volume
134,027 shs
Market Capitalization
$46.82 million
P/E Ratio
Dividend Yield
Price Target
MGEN stock logo

About Miragen Therapeutics Stock (NASDAQ:MGEN)

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.

MGEN Stock News Headlines

See More Headlines
Receive MGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Miragen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings

Industry, Sector and Symbol

Medical Laboratories
Current Symbol
Year Founded


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$4.46 million
Book Value
$6.78 per share


Free Float
Market Cap
$46.82 million
Not Optionable
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Jason A. Leverone CPA (Age 46)
    CPA, CFO, Sec. & Treasurer
    Comp: $355k
  • Dr. William Stuart Marshall Ph.D. (Age 56)
    Co-Founder & Sr. Technical Advisor
    Comp: $521k
  • Dr. Diana Escolar (Age 58)
    Chief Medical Officer
    Comp: $484.38k
  • Ms. Lee M. Rauch (Age 65)
    CEO & Director
  • Dr. Jonathan Violin Ph.D. (Age 45)
    Pres & COO
  • Eric N. Olson
    Co-Founder & Chairman of Scientific Advisory Board
  • Dr. Michael R. Bristow (Age 75)
    Co-Founder & Member of the Scientific Advisory Board
  • Dr. Marvin H. Caruthers (Age 80)
    Co-Founder & Scientific Advisory Board Member
  • Mr. Vahe Bedian Ph.D.
    Chief Scientific Officer
  • Dr. Aimee L. Jackson
    VP of Research

MGEN Stock Analysis - Frequently Asked Questions

How were Miragen Therapeutics' earnings last quarter?

Miragen Therapeutics, Inc. (NASDAQ:MGEN) announced its quarterly earnings results on Tuesday, November, 10th. The medical research company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.03. Miragen Therapeutics had a negative net margin of 1,393.50% and a negative trailing twelve-month return on equity of 141.66%.

What other stocks do shareholders of Miragen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Miragen Therapeutics investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), KushCo (KSHB), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), Organigram (OGI), Novan (NOVN) and Aeterna Zentaris (AEZS).

This page (NASDAQ:MGEN) was last updated on 5/30/2024 by Staff

From Our Partners